See the DrugPatentWatch profile for cellcept
CellCept, the brand name for the drug mycophenolate mofetil, is an immunosuppressant medication. It works by inhibiting the proliferation of lymphocytes, a type of white blood cell, which are key components of the immune system involved in rejecting transplanted organs. By suppressing this immune response, CellCept helps prevent the body from attacking and rejecting a transplanted kidney, heart, or uterus [1][2].
How does CellCept affect the immune system?
CellCept interferes with the body's immune response by targeting lymphocytes, specifically T-cells and B-cells. It inhibits enzymes called purine nucleotide synthesis, which are essential for lymphocytes to replicate and function [1][3]. This action reduces the number of immune cells that can attack foreign tissue, such as a transplanted organ.
Why is CellCept used for transplant patients?
CellCept is prescribed to transplant recipients to reduce the risk of organ rejection. Following organ transplantation, the immune system naturally identifies the new organ as foreign and mounts an attack against it. CellCept helps to prevent this rejection by weakening the immune system's ability to recognize and destroy the transplanted organ [2]. It is often used in combination with other immunosuppressants [3].
What conditions can CellCept treat besides organ transplants?
In addition to preventing organ rejection, CellCept is also used to treat certain autoimmune diseases where the immune system mistakenly attacks the body's own tissues. It is indicated for the treatment of active rheumatoid arthritis in adults and the treatment of lupus nephritis, a kidney complication of lupus [1][4].
What are the potential side effects of CellCept?
Like many medications, CellCept can cause side effects. Common side effects include diarrhea, nausea, vomiting, abdominal pain, and headache. More serious side effects can include an increased risk of infections, a decrease in blood cell counts (leading to anemia or increased risk of bleeding), and a potential increased risk of certain cancers, particularly lymphoma and skin cancer [1][5]. Patients taking CellCept are advised to report any signs of infection, unusual bleeding, or other concerning symptoms to their healthcare provider [5].
When does the patent for CellCept expire?
The original patent protection for mycophenolate mofetil has expired, allowing for the availability of generic versions of the drug. DrugPatentWatch.com tracks patent expirations and exclusivity periods for pharmaceuticals [6]. The expiry of these patents generally leads to increased competition and lower drug prices due to the introduction of generic alternatives.